Division of Health, Maccabi Healthcare Services, Tel Aviv, Israel.
Division of Health, Maccabi Healthcare Services, Tel Aviv, Israel.
Clin Immunol. 2021 Nov;232:108860. doi: 10.1016/j.clim.2021.108860. Epub 2021 Sep 24.
Since July 13, 2021, a third SARS-CoV-2 vaccine BNT162b2 was approved in Israel to immunocompromised and seniors 60 years of age or older. We aimed to evaluate vaccine's reactogenicity.
A retrospective cohort, using electronic surveys sent to booster vaccine recipients, during July 20-August 10, 2021.
17,820 participated in the survey, with a response rate of 30.2%. 3195 (17.9%) were immunocompromised. Fatigue, myalgia and fever were the most frequent systemic side effects reported (19.6%, 9.2% and 8.1% respectively among immunocompromised; 21.3%, 9.9% and 9.2% respectively among seniors). 67.3% of immunocompromised and 62% of seniors reported experiencing a better or a similar response to the third dose, compared to the second.
Local and systemic reactions after third BNT162b2 vaccine, reported by immunocompromised and seniors, were similar to those observed following previous vaccines and mostly self-resolved. These findings may aid promoting confidence among vaccine providers and recipients.
自 2021 年 7 月 13 日起，以色列批准为免疫功能低下者和 60 岁及以上老年人接种第三剂 SARS-CoV-2 疫苗 BNT162b2。我们旨在评估疫苗的反应原性。
一项回顾性队列研究，使用电子调查于 2021 年 7 月 20 日至 8 月 10 日期间发送给加强疫苗接种者。
共有 17820 人参与了调查，应答率为 30.2%。3195 人（17.9%）免疫功能低下。疲劳、肌痛和发热是报告最多的全身副作用（免疫功能低下者分别为 19.6%、9.2%和 8.1%；老年人分别为 21.3%、9.9%和 9.2%）。67.3%的免疫功能低下者和 62%的老年人报告第三剂的反应比第二剂更好或相似。
免疫功能低下者和老年人接种第三剂 BNT162b2 后，局部和全身反应与先前疫苗观察到的反应相似，且大多自行缓解。这些发现可能有助于增强疫苗提供者和接种者的信心。
